Literature DB >> 9287180

Interference with antigen processing by viruses.

H Hengel1, U H Koszinowski.   

Abstract

Viruses that establish persistent infections in their host, such as herpesviruses, adenoviruses or HIV, express proteins designed to pre-empt or evade recognition and elimination by MHC class I restricted CD8+ T lymphocytes. Notable discoveries during the annual period of review have demonstrated that, in principle, each single step within the MHC class I pathway of antigen processing and presentation is fair game for manipulation by viral functions. The viral factors that are natural inhibitors of this pathway have been instrumental for the elucidation of the distinct molecular mechanisms that are exploited by viruses. The viral stealth strategies that downregulate MHC class I protein surface expression may lead, however, to a higher susceptibility of virus-infected cells to natural killer cell activity. Strikingly, there is evidence that some viruses counteract increased natural killer cell recognition by expressing viral MHC class I homologues that function as surrogate inhibitors of natural killer cell activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287180     DOI: 10.1016/s0952-7915(97)80097-0

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  25 in total

1.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation.

Authors:  L Coscoy; D Ganem
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  MHC class I-subversive gene functions of cytomegalovirus and their regulation by interferons-an intricate balance.

Authors:  C Benz; H Hengel
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

Review 4.  Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections.

Authors:  Maurice R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

5.  Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.

Authors:  R Holtappels; J Podlech; G Geginat; H P Steffens; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Suppression of the interferon-mediated innate immune response by pseudorabies virus.

Authors:  Alla Brukman; L W Enquist
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 8.  Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions.

Authors:  Joana Loureiro; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

9.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 10.  Murine cytomegalovirus immune evasion proteins operative in the MHC class I pathway of antigen processing and presentation: state of knowledge, revisions, and questions.

Authors:  Niels A W Lemmermann; Annette Fink; Jürgen Podlech; Stefan Ebert; Vanessa Wilhelmi; Verena Böhm; Rafaela Holtappels; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2012-09-09       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.